SHR-A1811 + Trastuzumab Emtansine
Phase 3RecruitingDevelopment Stage
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Nov 20, 2023 → Apr 1, 2032
About SHR-A1811 + Trastuzumab Emtansine
SHR-A1811 + Trastuzumab Emtansine is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06126640. Target conditions include HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy.
What happened to similar drugs?
0 of 14 similar drugs in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06126640 | Phase 3 | Recruiting |
Competing Products
20 competing products in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy